Management doesn't help, after explaining the benefits of Pracinostat in AML patients:
"At the American Society of Hematology (ASH) Annual Meeting In December 2014, the company reported significant clinical activity from 33 evaluable patients in an open-label, single-arm Phase II study of Pracinostat and azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (AML). Further follow-up indicates that the response rate and overall survival of these patients continued to increase. To date, 12 patients have been on study for more than six months, including five who have surpassed one year. Data from all 50 patients enrolled in this study have been submitted for presentation at the European Hematology Association (EHA) Annual Congress in June 2015."
They added:
“AML represents another important component of our Pracinostat development strategy,” continued Dr. Gold. “We remain encouraged by the durable responses and long-term tolerability observed in our ongoing Phase II study and will continue to monitor these patients closely to get a better estimate of the survival benefit. However, we do not intend to initiate any further studies of Pracinostat and azacitidine until we have gained a more complete understanding of the totality of clinical data surrounding the combination. We expect to be in a position to share more information regarding these findings and future development plans for Pracinostat later this year.”
Why not to continue the studies?
Wasn't recently $45M offering for that purpose?
Why to wait for more information later this year?
Don't they have results since December and even a submitted presentation at EHA in June?
"We remain encouraged..." really? they show no confidence.
Can't believe last PR, this will hurt even more the price of the stock.
Sorry, I'm pissed off...promise not to post again on this board.
